Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide

Article Radiology, Nuclear Medicine & Medical Imaging

The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE

Chayenne H. A. M. Veerman et al.

Summary: According to guidelines, long-acting somatostatin analogues (LA-SSAs) should be discontinued prior to peptide receptor radionuclide therapy (PRRT). This study aimed to determine the effect of continued use of LA-SSAs during PRRT on the uptake of [Lu-177]Lu-HA-DOTATATE. The results showed that long-acting octreotide and lanreotide do not interfere with the uptake of [Lu-177]Lu-HA-DOTATATE in tumor lesions, but significantly decrease uptake in healthy liver parenchyma and spleen tissue.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging A Systematic Review

David Morland et al.

Summary: This systematic review aims to evaluate the effects of cSA administration on the uptake of tumors and healthy organs during SSTR imaging. The findings suggest that cSA administration can decrease spleen and liver uptake while improving the contrast between tumors and surrounding organs.

CLINICAL NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The Influence of Long-Acting Somatostatin Analogs on Ga-68-DOTATATE Uptake in Patients With Neuroendocrine Tumors

Youssef Chahid et al.

Summary: Patients treated with SSA have higher Ga-68-DOTATATE SUVmax TLR values, and the use of SSA is an independent predictor for SUVmax TLR ≥8.1.

CLINICAL NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging